Please visit answersincme.com/KUS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary medicine discusses the treatment of patients with non–cystic fibrosis bronchiectasis (NCFB) using dipeptidyl peptidase 1 (DPP1) inhibitors. Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting neutrophilic inflammation in non–cystic fibrosis bronchiectasis (NCFB); Describe the clinical impact of DPP1 inhibitors for treating NCFB, in the context of conventional therapy; Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanomaApply strategies to enhance outcomes for patients with NCFB as the treatment landscape evolves; and Apply strategies to enhance outcomes for patients with NCFB as the treatment landscape evolves.